{"page":{"totalFilteredElements":20},"studies":[{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p style=\"margin:0cm;margin-bottom:.0001pt;\">A phase 2b, randomized, blinded,\nplacebo-controlled trial investigating the efficacy and safety of visugromab\nversus placebo, both in combination with pembrolizumab, pemetrexed, and\ncis-/carboplatin, in participants with newly diagnosed metastatic non-squamous\nnon-small cell lung cancer (GDFATHER-LUNG-01)</p>","eudractNumber":"2024-516792-32","id":10166,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-01-14T11:32:55+01:00","shortTitle":"Catalym CTL-002-003 GDFATHER-LUNG-01","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)</div>","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T08:46:54+02:00","shortTitle":"D702FC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T13:32:01+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T09:29:01+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive NIS zu klinischen Outcomes bei Patienten mit fortgeschrittenem nicht kleinzelligem Lungenkrebs (NSCLC) mit EGFR Mutation unter Behandlung mit zugelassenem Amivantamab-haltigen Therapieschemata im Rahmen der standardm&#228;&#223;igen klinischen Praxis","eudractNumber":null,"id":11841,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T10:36:37+01:00","shortTitle":"Lepidoptera","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive nicht-interventionelle Studie (NIS) zur Untersuchung der Wirksamkeit von Tremilimumab &amp; Durvalumab + platinbasierter Chemotherapie (TDC) in Patient:innen mit metastasiertem nicht-plattenepithelialem NSCLC und Risikomutationen.","eudractNumber":null,"id":11012,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"KEAP1 (Kelch-like ECH-associated protein 1)","id":"mt_251"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"STK11 (Serine/threonine kinase 11)","id":"mt_253"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT06494540","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2025-02-04T10:40:14+01:00","shortTitle":"NAUTIC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","eudractNumber":null,"id":4357,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-01-01T09:45:26+01:00","shortTitle":"Nationales Netzwerk Genomische Medizin Lungenkrebs nNGM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">A Phase 2, Open-Label, Parallel Cohort Study of\nSubcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or\nMetastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>","eudractNumber":"2022-000526-21","id":8484,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"EGFR","id":"mt_1"}],"nctNumber":"NCT05498428","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-03-01T11:55:23+01:00","shortTitle":"PALOMA-2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"nNGM Task Force 5 Genetic Tumor Risk","eudractNumber":null,"id":8781,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-16T09:43:41+02:00","shortTitle":"Task Force 5 (nNGM)","therapeutical":false,"therapyLines":[]}]}